Haemonetics Co. to Post Q1 2025 Earnings of $1.02 Per Share, Zacks Research Forecasts (NYSE:HAE)

Haemonetics Co. (NYSE:HAE) – Equities researchers at Zacks Research increased their Q1 2025 earnings per share (EPS) estimates for shares of Haemonetics in a research note issued to investors on Tuesday, June 11th. Zacks Research analyst R. Department now anticipates that the medical instruments supplier will earn $1.02 per share for the quarter, up from their prior forecast of $1.01. The consensus estimate for Haemonetics’ current full-year earnings is $4.55 per share. Zacks Research also issued estimates for Haemonetics’ Q2 2025 earnings at $1.10 EPS, Q3 2025 earnings at $1.19 EPS, Q4 2025 earnings at $1.20 EPS, FY2025 earnings at $4.51 EPS, Q1 2026 earnings at $1.32 EPS, Q2 2026 earnings at $1.28 EPS, Q3 2026 earnings at $1.09 EPS, FY2026 earnings at $5.00 EPS and FY2027 earnings at $5.99 EPS.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, May 9th. The medical instruments supplier reported $0.90 EPS for the quarter, topping the consensus estimate of $0.88 by $0.02. The business had revenue of $343.00 million for the quarter, compared to the consensus estimate of $329.53 million. Haemonetics had a return on equity of 22.25% and a net margin of 8.98%. The firm’s revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the business posted $0.77 EPS.

Other analysts also recently issued research reports about the company. StockNews.com downgraded Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. JMP Securities lifted their price target on Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research note on Friday, May 10th. TheStreet downgraded Haemonetics from a “b-” rating to a “c+” rating in a research note on Thursday, February 29th. Needham & Company LLC raised Haemonetics from a “hold” rating to a “buy” rating and set a $112.00 price target on the stock in a research note on Wednesday. Finally, Barrington Research lifted their price target on Haemonetics from $105.00 to $107.00 and gave the company an “outperform” rating in a research note on Friday, May 10th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $109.50.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $85.96 on Wednesday. The company has a market capitalization of $4.38 billion, a PE ratio of 37.54, a PEG ratio of 1.57 and a beta of 0.37. Haemonetics has a 12 month low of $70.74 and a 12 month high of $97.97. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. The stock’s fifty day simple moving average is $88.95 and its 200 day simple moving average is $83.54.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. TFO Wealth Partners LLC lifted its position in Haemonetics by 29,450.0% during the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock worth $51,000 after acquiring an additional 589 shares during the last quarter. Group One Trading L.P. acquired a new stake in Haemonetics during the third quarter worth approximately $55,000. Covestor Ltd lifted its position in Haemonetics by 184.8% during the first quarter. Covestor Ltd now owns 675 shares of the medical instruments supplier’s stock worth $58,000 after acquiring an additional 438 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in Haemonetics during the first quarter worth approximately $86,000. Finally, Parkside Financial Bank & Trust lifted its position in Haemonetics by 17.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 156 shares during the last quarter. Institutional investors own 99.67% of the company’s stock.

Insider Activity

In other news, EVP Anila Lingamneni sold 2,305 shares of the firm’s stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total value of $218,975.00. Following the completion of the transaction, the executive vice president now owns 12,295 shares in the company, valued at approximately $1,168,025. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, EVP Anila Lingamneni sold 2,305 shares of Haemonetics stock in a transaction dated Monday, May 6th. The stock was sold at an average price of $95.00, for a total transaction of $218,975.00. Following the completion of the transaction, the executive vice president now owns 12,295 shares in the company, valued at $1,168,025. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stewart W. Strong sold 686 shares of Haemonetics stock in a transaction dated Monday, May 20th. The stock was sold at an average price of $95.11, for a total value of $65,245.46. Following the transaction, the insider now owns 18,196 shares of the company’s stock, valued at approximately $1,730,621.56. The disclosure for this sale can be found here. Insiders sold 27,380 shares of company stock worth $2,445,816 in the last quarter. Corporate insiders own 1.79% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.